Natus Medical Announces Preliminary Revenue for the First Quarter 2016
April 04 2016 - 7:00AM
Natus Medical Incorporated (NASDAQ:BABY) today
announced preliminary revenue for is first quarter ended March 31,
2016.
Revenue for the first quarter of 2016 is expected to be
approximately $87.5 million versus previous guidance of $91.5
million to $92.5 million, excluding revenue from the Venezuela
Ministry of Health contract.
“Pushouts of key orders in both our international and domestic
markets led to weaker than expected revenue late in the first
quarter,” said Jim Hawkins, President and Chief Executive Officer
of the Company. “In addition, we did not have any revenue
associated with the Venezuela Ministry of Health contract as we did
not receive any prepayments during the quarter."
First Quarter 2016 Conference Call Schedule
Natus has scheduled an investment-community
conference call to discuss its financial results for the first
quarter of 2016 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time)
Wednesday April 20, 2016. Individuals interested in listening to
the conference call may do so by dialing 1-888-765-3164 for
domestic callers, or 1-503-406-4075 for international callers, and
entering reservation code 80936622. A telephone replay will be
available for 48 hours following the conclusion of the call by
dialing 1-855-859-2056 for domestic callers, or 1-404-537-3406 for
international callers, and entering reservation code 80936622.
The conference call also will be available
real-time via the Internet at http://investor.natus.com and a
recording of the call will be available on the Company's Web site
for 90 days following the completion of the call.
About Natus Medical
Incorporated
Natus is a leading provider of healthcare
products used for the screening, detection, treatment, monitoring
and tracking of common medical ailments in newborn care, hearing
impairment, neurological dysfunction, epilepsy, sleep disorders,
and balance and mobility disorders.
Additional information about Natus Medical can be found at
www.natus.com.
More information about potential risk factors that could affect
the business and financial results of Natus is included in Natus'
annual report on Form 10-K for the year ended December 31, 2015,
and its quarterly reports on Form 10-Q, and in other reports filed
from time to time by Natus with the U.S. Securities and Exchange
Commission.
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995,
particularly the statement regarding anticipated revenue for the
first quarter of 2016. This statement relates to current estimates
and assumptions of our management as of the date of this press
release, and future events or Natus' future financial performance
or results, and involve known and unknown risks, uncertainties and
other factors that may cause actual results, levels of activity,
performance, or achievements to differ materially from those
expressed or implied by the forward-looking statements.
Forward-looking statements are only predictions and the actual
events or results may differ materially. Natus cannot provide any
assurance that its future results or the results implied by the
forward-looking statements will meet expectations. Our future
results could differ materially due to a number of factors,
including the effects of competition, the demand for our products
and services, the impact of adverse global economic conditions on
our target markets, our ability to expand our sales in
international markets, our ability to maintain current sales levels
in a mature domestic market, our ability to control costs, risks
associated with bringing new products to market and integrating
acquired businesses, and our ability to fulfill product orders on a
timely basis. Natus disclaims any obligation to update information
provided in this release.
COMPANY CONTACT: Natus Medical Incorporated
Jonathan A. KennedySr. Vice President and Chief Financial
Officer(925) 223-6700InvestorRelations@Natus.com
PishPosh (NASDAQ:BABY)
Historical Stock Chart
From Jun 2024 to Jul 2024
PishPosh (NASDAQ:BABY)
Historical Stock Chart
From Jul 2023 to Jul 2024